|
|
Volumn 89, Issue 7, 2002, Pages 671-680
|
|
Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancer
|
|
Author keywords
Bacillus Calmette Gu rin; Immunotherapy; Intravesical therapy; Superficial bladder cancer
|
|
Indexed keywords
BCG VACCINE;
ADULT;
AGED;
ARTICLE;
BLADDER CARCINOMA;
CANCER GROWTH;
CANCER INVASION;
CANCER MORTALITY;
CANCER RECURRENCE;
CANCER STAGING;
CANCER SURVIVAL;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DOSE RESPONSE;
DRUG EFFECT;
DRUG EFFICACY;
DRUG INSTILLATION;
DRUG WITHDRAWAL;
FEMALE;
FOLLOW UP;
HUMAN;
IMMUNOTHERAPY;
MAJOR CLINICAL STUDY;
MALE;
MULTIPLE CANCER;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
SURVIVAL TIME;
TRANSURETHRAL RESECTION;
TREATMENT OUTCOME;
ADJUVANTS, IMMUNOLOGIC;
ADMINISTRATION, INTRAVESICAL;
ADULT;
AGED;
BCG VACCINE;
CYSTECTOMY;
DISEASE PROGRESSION;
DISEASE-FREE SURVIVAL;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
MALE;
MIDDLE AGED;
MULTIVARIATE ANALYSIS;
NEOPLASM RECURRENCE, LOCAL;
PROSPECTIVE STUDIES;
RISK FACTORS;
URINARY BLADDER NEOPLASMS;
|
|
EID: 0036228806
PISSN: 14644096
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1464-410X.2002.02722.x Document Type: Article |
|
Times cited : (183)
|
|
References (26)
|
